Paxlovid is an antiviral combination therapy that can reduce the risk of COVID-19 causing severe illness, hospitalization and ...

Nirmatrelvir is a protease inhibitor that stops the SARS-CoV-2 virus from replicating while ritonavir boosts the activity of nirmatrelvir. It is given in a five-day course with three pills taken twice ...

Tens of thousands of Americans are hospitalized with COVID-19 every week. Thousands die from it every month. And yet, an antiviral treatment proven to lessen the chances of severe outcomes is ...

Paxlovid is the most commonly prescribed at home treatment for COVID-19 in the U.S. It is approved to treat COVID in adults who are at risk of severe complications from the illness.

People who took Pfizer’s antiviral treatment Paxlovid shortly after infection saw a 26% lower risk of long Covid compared with those who didn’t, the study said.

FDA researchers estimated, based on Covid rates in January, that Paxlovid could "lead to 1,500 lives saved and 13,000 hospitalizations averted each week" in the U.S.

When Paxlovid was first authorized for emergency use in the U.S. in December 2021, it was free for anyone who needed it. Once the government stopped funding the treatment, Pfizer set a list price ...

Paxlovid isn't the only antiviral medication for COVID-19. Merck’s Lagevrio is another available pill, though it's proven to be less popular in the U.S. than Paxlovid.

Most people who take Paxlovid for the treatment of COVID do not get rebound COVID, but up to 20% of patients do. That doesn't mean that the drug isn't doing its job.

When Paxlovid was first authorized for emergency use in the U.S. in December 2021, it was free for anyone who needed it. Once the government stopped funding the treatment, Pfizer set a list price ...